| Management target | Revenue FY27 |
|---|
| Revenue growth | 13.9% YoY; CDMO segment up 18.6%. |
|---|---|
| Margins | EBITDA margins improved 238 bps YoY to 15%. |
| Order book | USD 25M Zambia order on track for H2 recognition. |
| Demand visibility | Strong CDMO demand; healthy visibility for Q2. |
| Management confidence | High for double-digit volume growth in coming quarters. |
Growth
Revenue rose 13.9% YoY to INR 1,167 Cr; EBITDA grew 35.4% YoY; PAT up 56.1% YoY to INR 101 Cr.
Outlook
Guided for 14-15% EBITDA margins; new Baddi facility live by fiscal end; Zambia revenue recognition in H2FY27.
Risks
API price volatility, muted international branded formulations performance, and temporary margin impact from expanded field force in domestic segments.
Last quarter's promises, checked
Delivered
- Guided double-digit CDMO volume growth → delivered 18.6% CDMO revenue growth (= BEAT)
- Guided 29% effective tax rate → delivered 29% (= BEAT)
- Guided FY26 capex of ~INR 222 Cr → delivered INR 222 Cr (= BEAT)
Partly delivered
- Guided 13-14% CDMO margins → delivered 15% (= BEAT)
- Guided Zambia supplies to start Q2FY27 → delayed to H2FY27 (= PARTIAL)
Missed
- Guided domestic branded growth above IPM rates → delivered 7.3% vs 8-9% IPM (= MISS)
Earnings Call Transcript filed with BSE, NSE: AKUMS. Summary written with AI assistance from the document.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹822.55
- Market cap
- ₹12,946 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 44.4×Sector 47.3×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 1.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2025, in compliance with SEBI LODR regulations.
Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Akums reported strong Q1 FY27 results with 13.9% revenue growth and 56.1% PAT growth. Strategy focuses on CDMO volume growth and expanding skincare/wellness via the Oriflame India manufacturing acquisition.
Akums Drugs & Pharmaceuticals Results Update
Akums Drugs reported Q1 FY27 consolidated revenue of ₹1,167 crore, reflecting 13.9% year-on-year growth. PAT rose to ₹101 crore compared to ₹65 crore in Q1 FY26.
Akums Drugs & Pharmaceuticals Q1 FY27 Results: Net Profit ₹101 Cr, Up 56.1% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,167 Cr (+13.9% YoY) and net profit of ₹101 Cr (+56.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹101 Cr · +56.1% YoY